FABP4 blocker attenuates colonic hypomotility and modulates white adipose tissue-derived hormone levels in mouse models mimicking constipation-predominant IBS.
P MosińskaD JacenikM SałagaA WasilewskiA CygankiewiczA SibaevA MokrowieckaE Małecka-PanasI PintelonM StorrJ P TimmermansW M KrajewskaJakub FichnaPublished in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2017)
Fatty acid binding protein 4 may be involved in IBS pathogenesis and become a novel target in the treatment of constipation-related diseases.